Antimicrobial properties of distinctin in an experimental model of MRSA-infected wounds.
The aim of this study was to evaluate the efficacy of distinctin in the management of cutaneous methicillin-resistant Staphylococcus aureus (MRSA) wound infections in an experimental mouse model. Wounds, made in the panniculus carnosus of BALB/c mice, were inoculated with 5 × 10(7) colony-forming units (CFU) of MRSA. Mice were treated with topical distinctin (1 mg/kg of body weight), topical teicoplanin (7 mg/kg of body weight), intraperitoneal teicoplanin (7 mg/kg of body weight); topical teicoplanin and daily intraperitoneal teicoplanin; topical distinctin and daily intraperitoneal teicoplanin. Bacterial cultures of excised tissues and histological examination of microvessel density and of vascular endothelial growth factor (VEGF) expression were studied. It was found that topical distinctin combined with parenteral teicoplanin inhibited bacterial growth to levels comparable with those observed in uninfected animals. Wounded areas of animals treated with distinctin were characterized by a more mature granulation tissue, with a more organized and denser type of connective tissue, compared to mice treated only with teicoplanin. Treatment with topical distinctin had a significant impact on VEGF expression and microvessel density. The combined use of distinctin with teicoplanin may be useful in the management of infected wounds by significantly inhibiting bacterial growth and accelerating the repair process.
Department of Dermatology, Università Politecnica delle Marche, Ancona, Italy. o.simonetti@univpm.it
O
O
Simonetti
O
O
Cirioni
R
R
Ghiselli
G
G
Goteri
F
F
Orlando
L
L
Monfregola
S
S
De Luca
A
A
Zizzi
C
C
Silvestri
G
G
Veglia
A
A
Giacometti
M
M
Guerrieri
A
A
Offidani
A
A
Scaloni
D000287:Administration, Topical; D029845:Amphibian Proteins / Q000008:administration & dosage*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D023181:Antimicrobial Cationic Peptides / Q000008:administration & dosage*; D058491:Bacterial Load; D004195:Disease Models, Animal; D006651:Histocytochemistry; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity; D051379:Mice; D008807:Mice, Inbred BALB C; D012867:Skin / Q000382:microbiology / Q000473:pathology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology; D017334:Teicoplanin / Q000008:administration & dosage; D016896:Treatment Outcome; D014946:Wound Infection / Q000188:drug therapy* / Q000382:microbiology
D029845:Amphibian Proteins; D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; C531945:distinctin; D017334:Teicoplanin